Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Tower Laboratories Ltd.
WARNING LETTER
•Tower Laboratories Ltd.•July 11, 2025

Tower Laboratories Ltd. – FDA Warning Letter, Jul 11, 2025

Record Details

The FDA issued a Warning Letter to Tower Laboratories Ltd. following an inspection from July 8-11, 2025, at its Montague, MI drug manufacturing facility. The letter outlines significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals (21 CFR parts 210 and 211), leading to the adulteration of the company’s drug products under the Federal Food, Drug, and Cosmetic Act.

Key violations include the failure to thoroughly investigate out-of-specification (OOS) laboratory results for over-the-counter (OTC) drug products, particularly concerning stability failures. The company repeatedly attributed OOS results to "microscopic packaging defects" without adequate scientific evidence or implementing effective corrective and preventive actions (CAPA), a repeated observation from a previous inspection. Furthermore, customers were not notified of these failing stability results for distributed lots.

The FDA also cited Tower Laboratories Ltd. for failing to establish adequate laboratory controls. Specifically, their sample preparation methods for high-performance liquid chromatography analysis were unsuitable, using a solvent that degrades the active ingredient, potentially generating inaccurate OOS results.

To address these issues, the FDA requires Tower Laboratories Ltd. to conduct a retrospective, independent review of all invalidated OOS results for U.S. products, identifying conclusive root causes and remediating affected methods. The company must also provide a comprehensive remediation plan for its OOS investigation systems, enhancing quality unit oversight, root cause evaluation, and CAPA effectiveness. Finally, an evaluation and retrospective review of all analytical sample preparation methods, including a risk assessment of past test results, is mandated.

Company
Tower Laboratories Ltd.
Inspection date
July 11, 2025
Product type
Drugs
Office
Center for Drug Evaluation and Research
People
  • Norman Needleman
  • Renee A. Marcsisin
  • Francis Godwin (Director)
View Company Profile

ID · f07c54c7-3125-4639-bd8c-325bb5d94a94

Violation Codes6
21 U.S.C. 351(a)(2)(B)21 CFR 21021 CFR 211FD&C Act 501(a)(2)(B)21 CFR 211.19221 CFR 211.160(b)

Full citation text and observation details available on the Dashboard.

Other documents for Tower Laboratories Ltd.
  • 483 - 2025-07-11July 11, 2025
  • 483 - 2021-11-17November 17, 2021
  • 483 - 2019-05-02May 2, 2019

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Tower Laboratories Ltd.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.